Por: The Boston Globe Business September 28, 2022
Biogen and its partner Eisai said Tuesday night that their experimental Alzheimer’s disease therapy successfully slowed the memory-robbing condition in a large clinical trial. The results set the stage for potential approval of the drug next year.Although far from a cure, the therapy provides tentative hope to the millions of Americans afflicted by the devastating disease. It also offers the beleaguered Cambridge biotech firm a second chance... + full article
ABC News USA Business September 29, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after ’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
How To Spot The Early Signs Of Alzheimer's | Newsweek
Chicago Tribune USA Business September 28, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study. Eisai announced results late Tuesday from a global study... + más
Orlando Sentinel USA Business September 28, 2022
Fox Business USA Business September 28, 2022
Dr. Stephen O'Brien, chief medical officer of Mediflix, shares how his streaming platform is trailblazing access to medical information for everyone. Shares of Biogen surged Wednesday's following news that its drug lecanemab showed promising signs of potentially... + más
Biogen shares rally as Alzheimer's drug results show promise | CBS News
Alzheimer's drug shows promise in early results of study | WPLG Local 10
ABC News USA Health September 28, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after ’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study. Eisai announced results late Tuesday from a global study of... + más
WPLG Local 10 USA Health September 28, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab,... + más
Associated Press USA Health September 28, 2022
About iurex | Privacy Policy | Disclaimer |